[TODO] Hook — anti-aging peptide research spans multiple mechanisms: collagen, telomeres, mitochondria, hormones — which have the strongest evidence?
[IMAGE: Anti-aging peptide landscape infographic — 4 categories with key compounds and evidence levels]
Categories of Anti-Aging Peptides
- [TODO] Collagen & skin — GHK-Cu, copper peptides, matrikines
- [TODO] Telomere maintenance — Epithalon
- [TODO] Mitochondrial / NAD+ — MOTS-c, Humanin, SS-31
- [TODO] Hormonal — GH secretagogues (Sermorelin, CJC/Ipamorelin), BPC-157
- [TODO] Senolytic — FOXO4-DRI (senescent cell clearance)
Top Compounds Ranked by Research Evidence
- [TODO] GHK-Cu — strongest evidence (human topical studies + gene expression data)
- [TODO] Epithalon — unique telomerase mechanism, but single-lab data primarily
- [TODO] GH Secretagogues — established HPA axis interaction, FDA-approved history
- [TODO] MOTS-c — promising but early-stage
- [TODO] FOXO4-DRI — exciting senolytic data but very limited
Combination Strategies
[IMAGE: Pyramid showing foundational, intermediate, and advanced anti-aging peptide stacks]
- [TODO] Foundation — GHK-Cu (skin/systemic) + GH secretagogue (hormonal)
- [TODO] Intermediate — add Epithalon cycles for telomere maintenance
- [TODO] Advanced — add NAD+ peptides, senolytics
- [TODO] Lifestyle synergy — exercise, sleep, nutrition amplify peptide effects
Safety & Practical Considerations
- [TODO] Start with well-characterized compounds (GHK-Cu, Sermorelin)
- [TODO] Baseline biomarkers — IGF-1, telomere length, inflammatory markers
- [TODO] Cycling — avoid continuous use for hormonal peptides
- [TODO] Cost-benefit — prioritize compounds with strongest evidence per dollar
Frequently Asked Questions
[FAQ: What is the single best anti-aging peptide to start with?]
[FAQ: Can anti-aging peptides reverse existing aging?]
[FAQ: How long before results are measurable?]
[FAQ: Are there synergies between anti-aging peptides and NAD+ precursors?]
Related Products
[TODO] Link to Anti-Aging category — GHK-Cu, Epithalon, NAD+ product pages
